149 related articles for article (PubMed ID: 8138668)
41. Antimicrobial activities of tosufloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella branhamella catarrhalis isolated from otolaryngological infectious diseases.
Suzuki K; Fujisawa T; Nakashima M; Hamasaki R
J Infect Chemother; 2005 Oct; 11(5):253-5. PubMed ID: 16258823
[TBL] [Abstract][Full Text] [Related]
42. [Colonization (infection) of the respiratory tract in outpatients in 2000-2005 years].
Kaczała M; Kopron K; Gmyrek J; Giedrys-Kalemba S
Pol Merkur Lekarski; 2008 Mar; 24(141):195-201. PubMed ID: 18634283
[TBL] [Abstract][Full Text] [Related]
43. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients.
Hansen CR; Pressler T; Hoiby N; Johansen HK
J Cyst Fibros; 2009 Jan; 8(1):58-62. PubMed ID: 18849202
[TBL] [Abstract][Full Text] [Related]
44. [On the bacteriology of chronic bronchitis].
Köhler H; Ezold R
Z Gesamte Inn Med; 1967 May; 22(9):257-62. PubMed ID: 4385675
[No Abstract] [Full Text] [Related]
45. Ciprofloxacin in acute exacerbations of chronic bronchitis.
Hoogkamp-Korstanje JA; Klein SJ
J Antimicrob Chemother; 1986 Sep; 18(3):407-13. PubMed ID: 3490468
[TBL] [Abstract][Full Text] [Related]
46. Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella (Branhamella) catarrhalis isolated in the UK from sputa.
Powell M; McVey D; Kassim MH; Chen HY; Williams JD
J Antimicrob Chemother; 1991 Aug; 28(2):249-59. PubMed ID: 1778856
[TBL] [Abstract][Full Text] [Related]
47. [Antibiotics therapy in chronic bronchitis].
Nolte D
Fortschr Med; 1979 Aug; 97(32):1350-5. PubMed ID: 39882
[TBL] [Abstract][Full Text] [Related]
48. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
Harrison CJ; Woods C; Stout G; Martin B; Selvarangan R
J Antimicrob Chemother; 2009 Mar; 63(3):511-9. PubMed ID: 19174454
[TBL] [Abstract][Full Text] [Related]
49. Bacteria and COPD exacerbations redux.
Hirschmann JV
Chest; 2001 Feb; 119(2):663-7. PubMed ID: 11171760
[No Abstract] [Full Text] [Related]
50. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis.
Sethi S; Breton J; Wynne B
Antimicrob Agents Chemother; 2005 Jan; 49(1):153-60. PubMed ID: 15616290
[TBL] [Abstract][Full Text] [Related]
51. Childhood asthma after bacterial colonization of the airway in neonates.
Bisgaard H; Hermansen MN; Buchvald F; Loland L; Halkjaer LB; Bønnelykke K; Brasholt M; Heltberg A; Vissing NH; Thorsen SV; Stage M; Pipper CB
N Engl J Med; 2007 Oct; 357(15):1487-95. PubMed ID: 17928596
[TBL] [Abstract][Full Text] [Related]
52. The epidemiology of respiratory tract pathogens in southern Netherlands.
Davies BI; Maesen FP
Eur Respir J; 1988 May; 1(5):415-20. PubMed ID: 3139445
[TBL] [Abstract][Full Text] [Related]
53. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
[TBL] [Abstract][Full Text] [Related]
54. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function.
Eller J; Ede A; Schaberg T; Niederman MS; Mauch H; Lode H
Chest; 1998 Jun; 113(6):1542-8. PubMed ID: 9631791
[TBL] [Abstract][Full Text] [Related]
55. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods.
Morrissey I; Robbins M; Viljoen L; Brown DF
J Antimicrob Chemother; 2005 Feb; 55(2):200-8. PubMed ID: 15649996
[TBL] [Abstract][Full Text] [Related]
56. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
Pfaller MA; Farrell DJ; Sader HS; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
[TBL] [Abstract][Full Text] [Related]
57. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
58. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease.
Sethi S; Evans N; Grant BJ; Murphy TF
N Engl J Med; 2002 Aug; 347(7):465-71. PubMed ID: 12181400
[TBL] [Abstract][Full Text] [Related]
59. [Clinical significance of fungal and microbial associations and antibacterial therapy for treatment of chronic inflammatory respiratory tract diseases in children].
Platonova MM; Sereda EV; Katosova LK
Antibiot Khimioter; 1998; 43(9):19-23. PubMed ID: 9791682
[TBL] [Abstract][Full Text] [Related]
60. A randomized double-blind controlled trial of roxithromycin and cefaclor in the treatment of acute lower respiratory tract infections in general practice.
Tilyard MW; Dovey SM
Diagn Microbiol Infect Dis; 1992; 15(4 Suppl):97S-101S. PubMed ID: 1617932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
